Drugs / cimlanod
cimlanod
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03515980 | May 2018 → Aug 2019 | congestive heart failure, liver failure | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03332186 | Mar → Oct 2018 | congestive heart failure, kidney failure | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03210909 | Jun → Jul 2017 | heart failure | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02932969 | Oct 2016 → May 2017 | heart failure | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02819271 | Feb → Apr 2014 | heart failure | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT03730961 | Jan → Dec 2019 | congestive heart failure | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT03357731 | Nov 2017 → May 2019 | left ventricular failure | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT03016325 | Jan 2017 → Jun 2019 | heart failure | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT02157506 | Jun 2014 → May 2015 | heart failure | Bristol-Myers Squibb | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03891108 Comparator | Feb → Jul 2019 | heart failure | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cimlanod | “Bristol-Myers Squibb-986231 (cimlanod) is an HNO donor being developed for acute heart failure (AHF).” PMID 33248986 ↗ Nov 2020 |
| Known as | BMS-986231 | “BMS-986231 is an HNO donor being developed as a therapy for heart failure” PMID 31168885 ↗ Jun 2019 |
| Known as | CXL-1427 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02157506 ↗ |
| Modality | Other / unclassified | “BMS-986231 is an HNO donor” PMID 31168885 ↗ Jun 2019 |
| Route | Intravenous | “continuous 6-hour IV infusions of CXL-1427” NCT02157506 ↗ |